NCT02769962 2025-07-28
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
Clinical Trials
10 trialsNCT03531827 2022-07-12
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02010567 2020-11-03
Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Terminated
NCT01803269 2020-06-26
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
University of Chicago
Phase 2 Terminated
NCT01380769 2020-05-28
A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer
Lumos Pharma
Phase 2 Completed
NCT02389985 2020-05-28
A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Lumos Pharma
Phase 1/2 Terminated
NCT02648711 2020-05-28
Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
Lumos Pharma
Phase 1 Terminated
NCT01625936 2018-08-29
CRLX101 Plus Bevacizumab in Advanced RCC
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01652079 2018-07-02
CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT01612546 2018-02-01
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
City of Hope Medical Center
Phase 2 Completed